Denosumab Global Safety Assessment Among Women With Postmenopausal Osteoporosis and Men With Osteoporosis in Multiple Observational Databases
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Denosumab (Primary) ; Osteoporosis therapies
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Amgen
- 11 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 14 Aug 2011 Trial details updated from abstract presented at 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
- 11 Jan 2010 New trial record.